Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone ER Open-Label Extension in Schizophrenia
NCT00645307Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2004
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of paliperidone in schizophrenia, sponsored by Johnson & Johnson. Primary endpoint: Long-term assessment of safety and tolerability at 52 weeks. Started May 2004; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00645307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00645307.